{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:35:42Z","timestamp":1722893742219},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T00:00:00Z","timestamp":1116806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T00:00:00Z","timestamp":1116806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2005,7,1]]},"DOI":"10.1038\/sj.bmt.1705007","type":"journal-article","created":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T09:11:48Z","timestamp":1116839508000},"page":"25-31","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)"],"prefix":"10.1038","volume":"36","author":[{"given":"C","family":"Bengala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Wandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-P","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Cure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Orlandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P F","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Demirer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the EBMT Solid Tumor Working Party","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,5,23]]},"reference":[{"issue":"Suppl. 7","key":"BF1705007_CR1","first-page":"47","volume":"27","author":"RF Ozols","year":"2000","unstructured":"Ozols RF . Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 2000; 27 (Suppl. 7): 47\u201349.","journal-title":"Semin Oncol"},{"key":"BF1705007_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1040-8428(99)00036-0","volume":"32","author":"PF Conte","year":"1999","unstructured":"Conte PF, Cianci C, Gadducci A . Update in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 1999; 32: 49\u201358.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF1705007_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/0090-8258(90)90080-5","volume":"38","author":"M Bruzzone","year":"1990","unstructured":"Bruzzone M, Repetto L, Chiara S et al. Chemotherapy vs radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 1990; 38: 392\u2013395.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.2003.11.018","volume":"21","author":"MA Varia","year":"2003","unstructured":"Varia MA, Stehman FB, Bundy BN et al. Intraperitoneal radioactive phosphorus (32P) vs observation after negative second-look laparoptomy for stage III ovarian carcinoma: a randomised trial of the gynaecologic oncology group. J Clin Oncol 2003; 21: 2849\u20132855.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR5","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 vs 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460\u20132465.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR6","first-page":"446","volume":"22","author":"S Pignata","year":"2003","unstructured":"Pignata S, De Placido S, Scambia G et al. Topotecan vs nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1 (Multicenter Italian Trials in Ovarian Cancer) study. Proc Am Soc Clin Oncol 2003; 22: 446 (Abstr).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1705007_CR7","first-page":"446","volume":"22","author":"J Pfisterer","year":"2003","unstructured":"Pfisterer J, Lortholary A, Kimmig R et al. Paclitaxel\/carboplatin (TC) vs Paclitaxel\/carboplatin followed by topotecan (TC-Top) in first line treatment of ovarian cancer FIGO stages IIb\u2013IV Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 2003; 22: 446 (abstr).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1705007_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","volume":"20","author":"B Barakat","year":"2002","unstructured":"Barakat B, Sabbatini P, Bhaskaran D et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002; 20: 694\u2013698.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1006\/gyno.1997.4689","volume":"65","author":"M Bruzzone","year":"1997","unstructured":"Bruzzone M, Rubagotti A, Gadducci A et al. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer with minimal residual disease at second-look: a prospective randomised trial of 111 patients. Gynecol Oncol 1997; 65: 499\u2013505.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001\u20131007.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR11","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950\u20131955.","journal-title":"N Engl J Med"},{"key":"BF1705007_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/gyno.1999.5677","volume":"76","author":"A Gadducci","year":"2000","unstructured":"Gadducci A, Carnino F, Chiara S et al. Intraperitoneal vs intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157\u2013162.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR13","first-page":"201a","volume":"21","author":"DK Armstrong","year":"2002","unstructured":"Armstrong DK, Bundy BN, Baergen R et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 2002; 21: 201a (Abstr).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1705007_CR14","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2550::AID-CNCR19>3.0.CO;2-R","volume":"77","author":"J-P Lotz","year":"1996","unstructured":"Lotz J-P, Bouleuc C, Andr\u00e8 T et al. Tandem high-dose chemotherapy with ifosfamide, carboplatin and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 1996; 77: 2550\u20132559.","journal-title":"Cancer"},{"key":"BF1705007_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/sj.bmt.1703036","volume":"27","author":"MG Salerno","year":"2001","unstructured":"Salerno MG, Ferrandina G, Greggi S et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 2001; 27: 1017\u20131025.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705007_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/gyno.2003.6882","volume":"88","author":"RJ Schilder","year":"2003","unstructured":"Schilder RJ, Brady MF, Spriggs D et al. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 3\u20138.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.bmt.1702468","volume":"26","author":"F Bertucci","year":"2000","unstructured":"Bertucci F, Viens P, Delpero JR et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant 2000; 26: 61\u201367.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705007_CR18","doi-asserted-by":"crossref","unstructured":"Cur\u00e8 H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO\/FNCLCC\/SFGM-TC study. Proc Am Soc Clin Oncol 2004; 23 Abstr. 5006).","DOI":"10.1200\/jco.2004.22.90140.5006"},{"key":"BF1705007_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.1997.15.4.1309","volume":"15","author":"PJ Stiff","year":"1997","unstructured":"Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent\/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309\u20131317.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1023\/A:1011136807190","volume":"12","author":"JA Ledermann","year":"2001","unstructured":"Ledermann JA, Herd R, Maraninchi D et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12: 693\u2013699.","journal-title":"Ann Oncol"},{"key":"BF1705007_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/sj.bmt.1704473","volume":"33","author":"ML Donato","year":"2004","unstructured":"Donato ML, Aleman A, Champlin RE et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004; 33: 1219\u20131224.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl. 2","key":"BF1705007_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1525-1438.2003.13360.x","volume":"13","author":"MJ Piccart","year":"2003","unstructured":"Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin vs no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 196\u2013203.","journal-title":"Int J Gynecol Cancer"},{"key":"BF1705007_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/gyno.2000.5805","volume":"78","author":"J-L Brun","year":"2000","unstructured":"Brun J-L, Feyler A, Chene G et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21\u201327.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1006\/gyno.2001.6328","volume":"82","author":"DS Chi","year":"2001","unstructured":"Chi DS, Liao JB, Leon LF et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82: 532\u2013537.","journal-title":"Gynecol Oncol"},{"key":"BF1705007_CR25","first-page":"107","volume":"6","author":"APM Heintz","year":"2001","unstructured":"Heintz APM, Odicino F, Maissonneuve P et al. Carcinoma of the ovary. In: FIGO Annual Report on the results of treatment in Gynecological Cancer. J Epidemol Biostat 2001; 6: 107\u2013138.","journal-title":"J Epidemol Biostat"},{"key":"BF1705007_CR26","first-page":"57","volume-title":"Important Advances in Oncology","author":"L Norton","year":"1991","unstructured":"Norton L, Day R . Potential innovations in scheduling of cancer chemotherapy. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. Lippincott: Philadelphia, PA, 1991, pp 57\u201372."},{"key":"BF1705007_CR27","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1200\/JCO.1998.16.5.1852","volume":"16","author":"C Aghajanian","year":"1998","unstructured":"Aghajanian C, Fennelly D, Shapiro F et al. Phase II study of \u2018dose dense\u2019 high-dose chemotherapy treatment with peripheral blood progenitor cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852\u20131860.","journal-title":"J Clin Oncol"},{"key":"BF1705007_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.bmt.1701659","volume":"23","author":"H Wandt","year":"1999","unstructured":"Wandt H, Birkmann J, Denzel T et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I\/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763\u2013770.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705007_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1046\/j.1537-2995.2001.41121577.x","volume":"41","author":"L Pierelli","year":"2001","unstructured":"Pierelli L, Perillo A, Ferrnadina G et al. The role of the growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomised comparison of G-CSF and GM-CSF. Transfusion 2001; 41: 1577\u20131585.","journal-title":"Transfusion"},{"key":"BF1705007_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s002620000158","volume":"49","author":"A Fattorossi","year":"2001","unstructured":"Fattorossi A, Battaglia A, Pierelli L et al. Effects of granulocyte-colony-stimulating factor and granulocyte\/macrophage-colony-stimulating factor administration on T-cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother 2001; 49: 641\u2013648.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705007","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:18:45Z","timestamp":1648081125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7,1]]}},"alternative-id":["BF1705007"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705007","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2005,5,23]]},"assertion":[{"value":"1 June 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}